Established in 2005
– Developed cell therapy products for over 10 years since 2005
– Internalization of core technologies to overcome technological hurdles faced by the existing cell therapy products
– Excellent researchers (in-house R&D/advisory committee)
– Active utilization of industry-academic joint research

2 Platform Technologies
– Embryonic stem cell differentiation standardization technology (TED technology)
– 3D cell spheroid formation technology (FECSTMtechnology)
– Owns a number of detailed technologies derived from 2 platform technologies
– Expands pipelines through detailed technologies and promote new projects derived therefrom

8 Pipelines
– CureSkin Inj. Product release
– Owns R&D pipelines centered on “Regenerative Medicine”
– Owns 4 clinical development pipelines
– Owns 5 pipelines targeting diseases without cure

Operating GMP facilities for more than 10 years
– Certification from the Ministry of Food and Drug Safety in 2010
– Completed standardization of manufacturing and quality control processes by securing know-how with long experience in operating GMP facilities
– S.Biomedics provides consigned testing services for cell therapy products and medicine related to cell therapy products required by biotech companies in Korea.